Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India

Indian Journal of Medical Research

Volumn 128, Issue 1, 2008, Pages 38-44

  Thakur, C P ^a,b   Kumar, Amit ^a   Mitra, Gaurab ^a   Thakur, Shabnam ^a   Sinha, P K ^a   Das, P ^a   Bhattacharya, S K ^a   Sinha, Arun ^a  

^a PATNA UNIVERSITY   (India)

^b Uma Complex   (India)

Author keywords

Amphotericin B (Fungizone); Post kala azar dermal leishmaniasis; Sodium antimony gluconate; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIMONY GLUCONATE;

ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EPIDEMIC; HUMAN; INCIDENCE; INDIA; INTERVIEW; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PARASITE CONTROL; SKIN LEISHMANIASIS; THERAPY RESISTANCE; TREATMENT DURATION; TREND STUDY; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; DISEASE OUTBREAKS; HUMANS; INCIDENCE; INDIA; LEISHMANIASIS, VISCERAL;

EID: 55849153521     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gupta PCS. Leishmaniasis. In: A handbook of tropical diseases; Banerjee JC, Bhattacharya PB, editors, Calcutta: Academic Publishers 1960; p. 103-40.
2. Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 1984; 78: 391-8.
3. Thakur CP, Kumar K, Sinha PK, Mishra BN, Pandey AK. Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate. BMJ 1987; 295: 86-7.
4. Thakur CP, Kumar K. Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes. Ann Trop Med Parasitol 1992; 86: 355-9.
5. Musa AM, Khalil EA, Raheem MA, Zijlstra EE, Ibrahim ME, Elhassan IM, et al. The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann Trop Med Parasitol 2002; 96: 765-72.
6. Kordofani YM, Nour YT, El-Hassan AM, Shalayel MH. Post kala-azar dermal leishmaniasis in Sudan. East Mediterr Health J 2001; 7: 1061-4.
7. Gasim S, Elhassan AM, Kharazmi A. Khalil EA, Ismail A, Theander TG. The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clin Exp Immunol 2000; 119: 523-9.
8. Gasim S, Elhassan AM, Khalil EA, Ismail A, Kadaru AM, Kharazmi A, et al. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol 1998; 111: 64-9.
9. Rathi SK, Pandhi RK, Chopra P, Khanna N. Lesional T-cell subset in post-kala-azar dermal leishmaniasis. Int J Dermatol 2005; 44: 12-3.
10. Ghosh MK, Nandy A, Addy M, Maitra TK, Ghose AC. Sub populations of T lymphocytes in the peripheral blood, dermal lesions and lymph nodes of post kala-azar dermal leishmaniasis patients. Scand J Immunol 1995; 41: 11-7.
11. Brahmachari UN. A new form of cutaneous leishmaniasis, dermal leishmanoid. Indian Med Gaz 1922; 57: 125-7.
12. Thakur CP, Singh RK, Hassan SM, Kumar R, Narai S, Kumar A. et al. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999; 93: 319-23.
13. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
14. Singh RP. Observation on dermal leishmanoid in Bihar. Indian J Dermatol 1968; 13: 59-63.
15. Dutta M, Ghosh TK. Review of current status of leishmaniasis epidemiology. In: Proceedings of the Indo-U.K. Workshop on Leishmaniasis, Dec 6-10, 1982; Patna. New Delhi: Indian Council of Medical Research; 1983. p. 97-102.
16. Peters W. The treatment of kala-azar-new approaches to an old problem. Indian J Med Res 1981; 73 (Suppl): 1-18.
17. Bora D. Epidemiology of visceral leishmaniasis in India, Natl Med J India 1999; 12: 62-8.
18. Government of India. Report of Expert Team on kala-azar programme assessment. New Delhi: Directorate of National Malaria Eradication Programme; 1994.
19. Manson-Bahr, PEC. Leishmaniasis: In: Manson's tropical diseases. Willcocks C, Manson-Bahr PEC, editors. London: Bailliere Tindal; 1972. p.117-47.
20. Thakur CP, Kumar M, Singh SK, Sharma D, Prasad US, Singh RS, et al. Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J 1984; 288: 895-7.
21. Thakur CP, Kumar M, Mishra BN, Pandey AK. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. B M J 1988; 296: 1557-61.
22. World Health Organization. Control of the Leishmaniasis. World Health Organization Tech Rep Ser No. 793. Geneva: WHO; 1990.
23. Thakur CP, Kumar K. Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis. Indian J Med Res 1990; 91: 144-8.
24. Thakur C P, Narain S, Kumar N, Hassan SM, Jha DK, Kumar A. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol 1997; 91: 611-6.
25. Thakur CP, Sinha GP, Sharma V, Pandey AK, Kumar M, Verma BB. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian J Med Res 1993; 97: 170-5.
26. Singh SP, Reddy DC, Rai M, Sundar S. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health 2006; 11: 899-905.
27. Lira R, Sundar S, Makharia A., Keeney R, Gam A, Saraiva E, et al. Evidence that the high incidence of treatment failures in kala-azar is due to the emergence of antimony resistant strains of Leshmania donovani. J Infect Dis 1999; 180: 564-7.
28. Hashsim FA, Khalil EA, Ismail, A EL Hassan AM. Apparently successful treatment of two cases of post kala-azar dermal leishmaniasis with liposomal amphotericin B. Trans R Soc Trop Med Hyg 1995; 89: 440.